Mera Pharmaceuticals, Inc.
MRPI
$0.00
$0.000.00%
| 10/31/2011 | 07/31/2011 | 04/30/2011 | 01/31/2011 | 10/31/2010 | |
|---|---|---|---|---|---|
| Revenue | 4.78% | -6.22% | -21.80% | -49.31% | -51.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.78% | -6.22% | -21.80% | -49.31% | -51.79% |
| Cost of Revenue | -64.86% | 114.22% | 36.84% | 67.13% | 64.06% |
| Gross Profit | 17.96% | -15.52% | -28.28% | -56.32% | -57.49% |
| SG&A Expenses | 63.87% | 1.15% | -26.31% | -37.50% | -48.67% |
| Depreciation & Amortization | -70.25% | -71.67% | -60.19% | -60.77% | -67.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.28% | -15.43% | -24.54% | -27.05% | -34.31% |
| Operating Income | 15.25% | 27.60% | 27.97% | -31.31% | -17.53% |
| Income Before Tax | 63.76% | -84.46% | -67.80% | -165.65% | -148.59% |
| Income Tax Expenses | 26.04% | 39.84% | 43.06% | 41.98% | 38.66% |
| Earnings from Continuing Operations | 65.09% | -97.05% | -78.70% | -198.33% | -178.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.09% | -97.05% | -78.70% | -198.33% | -178.99% |
| EBIT | 15.25% | 27.60% | 27.97% | -31.31% | -17.53% |
| EBITDA | 7.89% | 18.41% | 20.87% | -80.38% | -78.35% |
| EPS Basic | 60.00% | -150.00% | -120.00% | -175.00% | -150.00% |
| Normalized Basic EPS | 66.67% | 66.67% | 33.33% | -50.00% | -50.00% |
| EPS Diluted | 60.00% | -150.00% | -120.00% | -175.00% | -150.00% |
| Normalized Diluted EPS | 66.67% | 66.67% | 33.33% | -50.00% | -50.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
